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Abstract 
 
Background: Patients with acute leukemia (AL) have a higher risk of neutropenia. Central 
venous catheters (CVC) are indispensable devices during chemotherapy treatments and 
aplasia support. 
Purpose: This clinical research aims to improve central-line associated bloodstream 
infection (CLABSI) assessment related to neutropenia and CVC manipulations using 
evidence-based science. 
Methods: This is a single-center, retrospective cohort study reporting 28 patients 
diagnosed with AL, among 154 hospital admission episodes using a Hickman CVC for 
more than 72hour, undergoing chemotherapy treatment or in aplasia support from 
January 2013 to December 2015, at the Haematology Department of Portuguese Institute 
of Oncology (Porto). 
Results: Forty-two Hickman catheters concerning 2130 hospital admission days (2007 
catheter days) and overall 3032 CVC manipulations were reported. CLABSI was always 
reported in neutropenia admissions within cases presenting a median number of CVC 
manipulations superior to 15. Induction revealed superior duration of neutropenia (median 
19, range 38 to 1) than aplasia support (median 12, range 23 to 3) [p=0.000]. Considering 
cumulative neutropenia-days prior to CLABSI, no statistical significance was found 
between induction (median 6.5, range 13 to 2) and aplasia support (median 4, range 9 to 
1) [p=0.285]. No CLABSI risk between admissions undergoing neutropenia (induction and 
aplasia support) was found (RR 0.736, 95% CI, 0.311–1.745). Overall 6.47 CLABSI rate 
was reported, including 0.63 mucosal barrier injury microorganism ratio. 
Conclusion: We concluded that in neutropenic patients, undergoing induction therapy or in 
aplasia support, CLABSI risk increases along with cumulative neutropenia days prior 
CLABSI and CVC manipulations. The MBIm ratio should be included to CLABSI rates 
assessment in AL patients.  The specific characteristics of the patient, the product and the 
clinical practice (HAST framework) should be considered to promote the effectiveness of 
CVC clinical research. 
Key Words: CLABSI; Acute Leukemia; Mucosal Barrier Injury Microorganism; Central 
Venous Catheter; Neutropenia
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Resumo 
Introdução: Os doentes com Leucemia Aguda (LA) têm um grande risco de neutropenia. 
Os Cateteres Venosos Centrais (CVC) são instrumentos indispensáveis durante os 
tratamentos de quimioterapia e aplasia. 
Objetivo: Com este trabalho de investigação pretende-se a avaliação das bacteriémias 
associadas ao CVC (CLABSI) , tendo em conta a neutropenia e as manipulações do 
CVC, tendo por base a  prática baseada na evidência. 
Métodos: Este é um estudo de coorte retrospectivo unicêntrico, incluindo 28 doentes 
diagnosticados com LA, entre 154 internamentos, usando CVC-Hickman por mais de 72h. 
Estes foram submetidos a tratamento de quimioterapia ou encontravam-se em aplasia 
desde janeiro de 2013 a dezembro de 2015, na Unidade de Hematologia do Instituto 
Português de Oncologia do Porto. 
Resultados: Foram  estudados 42 cateteres Hickman referentes a 2130 dias de 
internamento (2007 dias de cateter), num total de 3032 manipulações de CVC. A  
identificaçao da CLABSI ocorreu sempre em internamentos com neutropenia e com uma 
mediana de manipulações superior a 15. Durante o período de indução verificou-se  uma 
duração superior da neutropenia (mediana 19, intervalo 38 a 1), do que durante o período 
de suporte de aplasia (mediana 12, intervalo 23 a 3) [p=0,000]. Considerando os dias 
cumulativos de neutropenia prévios a CLABSI, não foi encontrada diferença 
estatisticamente significativa entre indução (mediana 6.5, intervalo 13 a 2) e suporte de 
aplasia (mediana 4, intervalo 9 a 1) [p=0,285]. Não houve diferenças estatisticamente 
significativas de risco de CLABSI entre internamentos em neutropenia (indução e aplasia) 
(RR 0.736, IC 95%, 0.311-1.745). Foi reportada uma taxa de CLABSI de 6,47, incluindo 
uma razão de 0,63 de microorganismos de barreira da mucosa. 
Conclusão: Nos doentes neutropénicos, submetidos a tratamento de indução ou em 
suporte de aplasia, o risco de CLABSI aumenta juntamente com os dias prévios de 
neutropenia, e com o número de manipulações do CVC. A razão de MBIm deveria ser 
incluida na avaliação das taxas CLABSI. Sendo que, o doente, o produto e a prática 
devem ser considerados como variáveis efetivas na investigação clínica associada a 
CVCs. 
Palavras-chave: CLABSI; Leucemia aguda; Microorganismo de barreira da mucosa; 
Cateter Venoso Central; Neutropenia. 
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1. Introduction 
1.1 Neutropenia and bloodstream infections in AL patients 
Infectious diseases are important causes in both morbidity and mortality in hematology 
oncology patients. Patients with Acute Leukemia (AL), have a higher risk of neutropenia 
due to high-dose chemotherapy treatments (CT) and to malignancy itself. [1-3] Multiple 
chemotherapy cycles, antibiotic resistant bacteria and high transfusion rates are known 
predisposing factors that increase the incidence and prevalence of bloodstream infections 
(BSI). [4-6] 
The AL is considered a group of neoplasms characterized by the transformation, 
undifferentation and clonal expansion of hematopoietic stem cells in the peripheral blood, 
bone marrow, and/or other tissues. [7] The classification of AL was previously based only 
on morfologhy (French-American-British [FAB] classification) and immunophenotype 
(acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL]); now also relies on 
cytogenetic findings. Furthermore AL can also be stratified as de novo if acute leukemia 
arises without previous neoplastic treatment or secundary AL if the patient had a previous 
antineoplastic treatment. [8] 
Different AL subtypes led to different therapeutic approaches and different outcomes.  
AML is associated with high dose chemotherapy treatments in induction, that includes 
both cytarabine and anthracyclines (i.e, 7+3 and/or SWOG regimens), and consolidation. 
Adult patients with ALL are also treated  with aggressive and intense chemotherapy 
regimens, using multiple chemotherapy drugs in association. [7] 
At diagnosis and during induction a functional neutropenia, i.e. a neutrophil dysfunction 
originated by bone marrow failure, can be identified. In this phase there is a higher 
infection risk. Also the administration of myelossupresived chemothearapeutic agents with 
therapeutic intent, such methotrexate, cytarabine, cyclophosphamide, doxorubicin or 
etoposide can lead to neutropenia. [9] The National Comprehensive Cancer Network 
(NCCN) considered neutropenia as the absolut neutrophil count (ANC) less than 500/µL 
or ANC less than 1000/mcL and predicted decline to 500/mcL or less over the next 48 
hours. [10] The rate of decline of the ANC and the duration of neutropenia are considered 
as major factors to determine the infection risk. The evaluation of collateral therapeutics 
as corticosteroids (especially linked to CT admissions) or granulocyte colony stimulating 
grow factors can impair neutrophil function and delay neutrophil recovery, [11-12] leading 
to the hiding of clinical signs and symptoms in the infection episodes. [10] 
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When a clinical infection episode is reported, blood cultures (BCs) should be obtained. 
Fever (temperature ≥ 38.3ºC or temperature ≥ 38ºC persisting for more than one hour) is 
considered the most important nonspecific sign of infection in neutropenic patients. [10,13] 
BCs indication includes the presence of fever or, in their absence, the presence of other 
signs or symptoms of infection (chills or hypotension). [10] In the management of BCs, in 
neutropenic patients with fever, the number of sets obtained through the catheter and 
peripheral vein needed is not consensual. [13] However, the approach of obtaining BCs 
from the central catheter lines and a peripheral vein to determine the source of BSI based 
on the differential time to positivity (DTP) is considered an important procedure. [13-15] In 
a first infection event, large spectrum antibiotherapy is started as the Guidelines for 
Intravascular Catheter-related Infection of Infectious Diseases Society of America (IDSA) 
recommends, including gram-negative bacteria infections in neutropenic patients. [16] 
In neutropenic patients, the natural host defense against local flora is reduced. AL patients 
undergoing CT can experience several complications, such as oral and gastrointestinal 
mucositis. [10, 17-18] Direct invasion across the colonic mucosa, due to the epithelial cell 
loss, can predispose patients to BSI. [18] Considering the National Healthcare Safety 
Network (NHSN) mucosal barrier injury microorganisms (MBIm) classification (2017) [19-
20] and NCCN disruption of mucosal barriers insight [10], the viridians group Streptococci, 
Enterococci spp., E. coli, Klebsiella and Enterobacter spp are considered the most 
representative species associated with alimentary, sinopulmonary and genitourinary 
infection tracks. [10,19-20] 
Several studies have identified the biofilm formation by individual multi-resistant 
pathogens as the major source of CVC infection. [21] The biofilm can be defined as 
communities of microorganisms attached to a surface. [22] The bacteria can initiate 
biofilm formation in response to a specific environmental impulse, such temperature, 
osmolarity, pH, iron, oxygen and nutrition. [22] 
The pathogenesis of CVC infections includes two major routes: extraluminal (associated 
to short-term cvcs) and intraluminal (associated with long-term CVC). The colonization of 
the intraluminal route from the catheter tubing connection, catheter hub or IV fluids, are 
considered the most important infection threats. [23] Coagulase-negative Staphylococcus 
(CoNS), Staphylococcus aureus, Pseudomonas aeruginosa and Enteric gram negatives 
are considered the most common microorganisms involved in central-line devices 
infections, being the Staphylococcus spp considered the most representative. [24] 
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1.2 Central Venous Catheters 
In 1929 Werner Forssmann discovered a new safety method in animals to introduce 
cardio-active drugs inserting a long urinary catheter via the antecubital fossa to the heart. 
He was awarded in 1956 with the Nobel Prize [25]; this was considered the first step in the 
journey of the central venous catheters (CVC). With the fastest-growing of the treatments, 
a new kind of long-term catheters were needed due to the different type of treatment 
modalities that allowed the administration of intravenous therapy, transfusion support and 
blood sampling [26] 
There are four major catheter types based on their designs: Non-tunnelled CVCs, 
Tunnelled CVCs (i.e, Hickman or Broviac catheters), Implantable ports and peripherally 
inserted central catheter (PICC). [27] The placement and type of CVC depends on the 
preferences of the patient, the healthcare provider and the IV therapy duration. [28] The 
principal way for healthcare professionals to reduce and control the pathogenesis of 
infections in central line devices are the insertion and maintenance procedures. [23] 
Several studies report behavioral changes, education of healthcare professionals, 
insufficiently trained nurses, a low nurse-to-patient ratio and protected environments 
directly related to infection control strategies. [29-31] 
Healthcare and Technology Synergy (HAST) framework considered that the patient, the 
product and practice are the central elements related with effectiveness of clinical 
research associated to CVC. [32] Insertion CVC procedure was largely studied and 
compared with the maintenance of CVC procedure. [33] The real value of CVC 
management still remains unclear due to the low description and few management 
detailed reports in clinical research. [29-33] 
Catheter-related occlusion due to mechanical obstructions and catheter-related infection 
are the most important complications in the management of the central venous devices. 
[5, 34] In AL inpatients the risk of these complications is high due to myelossupresion, 
specially neutropenia and thrombocytopenia. [35-36] The most common modifiable risk 
factors known to increase overall catheter-related bloodstream infection (CRBSI) are 
CVC-life [14], parenteral nutrition [37], multi-lumen CVC [38], high workload [39] or CVC-
associated thrombosis [34], being the imunocompromised status the highlighted non-
modifiable risk factor in hematology oncology patients. [2,40] 
Large osmolarity spectrum drugs, several infusion and perfusion volumes and lower 
thromboses rates lead Hickman catheters to be suggestted as the best vascular access 
devices option in AL patients undergoing high dose CT since 80´s decade. [28] Ming Y. 
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Ling et al.,  2013, developed at Mayo Clinic Rochester a clinical research comparing the 
efficacy of 84 Hickman Catheters versus 64 PICCs in the treatment of AML patients. The 
study reported no significant differences in catheter-related thrombosis, central-line 
associated bloodstream infections (CLABSI) and CRBSI rates. However, catheter-related 
occlusion was significant higher in PICCs (20.43 versus 1.25 per 1000 CVC-days, 
p=.0001). [28] 
Tunneled catheters report lower infection risk than non-tunneled catheters. [40] Mollee, et 
al., 2011, determined the incidence and risk factors for CABSI (CLABSI definition 
according to the Australian Infection Control Association) of all patients requiring a central 
venous access device (CVAD) in a hematology-oncology department. They considered 
the CVAD type, patient diagnosis, side of insertion and the number of prior-line insertions 
as risk factors of CABSI. The study suggests that the superior CABSI risk in right-sided 
lines (HR: 1.60; p=0.027) when  a higher number of previous lines were inserted (HR: 1.2; 
95% CI: 1.03-1.41). Considering hematological malignancies group (acute leukemia, 
myelodisplastic syndrome, non-Hodgkin Lymphoma and multiple myeloma), superior 
CABSI risk  was reported (HR: 3.17; 95% CI: 1.63-6.16). When CVAD type (tunneled lines 
versus PICCs) and aggressive hematological malignancies group (AL and myelodisplastic 
syndrome) were associated with the analysis, no significant CABSI risk was found (HR 
1.43; p=0.12) between them. Study results revealed that progressive use of CVC-lumens 
didn’t increase the infection risk. However the infection is  earlier reported in CVCs with 
more lumens (3 versus 2). In the case of Exit-site and Tunnel infections, hematological 
recovery was required for infection resolution. [41] 
1.2.1 Management of CVC: insertion and maintenance 
As recommended CVC insertion procedure takes place in a operating room to reduce the 
infection risk. CVC-placement (jugular or subclavian) and CVC-life are considered 
infection risk factors. [29] Glaucia Martinho, et al., 2013,developed a clinical research in 
56 patients undergoing HTSC (Hematological Transplantation Stem Cell) reporting 
significant differences between the jugular (ID: 31.7 per 1000 CVC-days) and subclavian 
(ID: 4.2 per 1000 CVC-days) CVC-placement (HR, 0.21 ;95% CI: 0.62-0.74, p=.02). [42] 
Walter Zing and Didier Pittet, members of the Infection Control Program and WHO 
Collaborating Centre on Patient Safety (Geneva), suggests in a comment of The Lancet 
(2016) that studies published between 2014 to 2016 report that subclavian access site is 
better than the jugular. [43] 
25 
 
Eitan Kugler, et al.2015, compared CVC-placement time <7 days versus ≥ 7days in a 
prospective surveillance study in patients with AL. The study suggests an association 
between late CVC-placement time and CLABSI (OR 3.4, 95% CI 1.1-10-45, p=.03). [36] 
Parienti,et al. 2015, published a systematic review entitled “Intravascular complications of 
central venous catheterization related to CVC-placement” in the New England Journal of 
Medicine. The study suggests that a jugular insertion site and that CVC-placement time 
can be considered extrinsic risks of CLABSI, and both can be modified. [44] 
The clinical research related to CVC maintenance procedures in AL patients is scarce. 
[29-30] Guidelines for the prevention of Intravascular Catheter-Related infections 
published by the Control Disease Center (CDC) in 2011 are based on education and 
training of CVC procedures. [31] There is a lack of clinical research, concerning CVC 
management details with different methodology  between studies that can improve and 
sustain the development of Guidelines. Only 45.5% of the major recommendations are 
considered category IA (strongly recommended for implementation and strongly 
supported by well-designed experimental, clinical, or epidemiologic studies). Considering 
the administration sets replacement and needleless intravascular catheter systems, 
46.14% of the recommendations are classified as Unsolved Issue and/or category II 
(suggested for implementation and supported by suggestive clinical or epidemiologic 
studies or a theoretical rationale). [31] The implementation of multifaceted strategies 
(bundled) to prevent intravascular catheter-related infections is based on recommended 
practices, category IB (strongly recommended for implementation and supported by some 
experimental, clinical, or epidemiologic studies and a strong theoretical rationale; or an 
accepted practice supported by limited evidence) or superior. [31] 
The National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections 
in NHS Hospitals in England (epic) and CDC guidelines reported, similar 
recommendations for catheter management. [45] In 2013, last update (epic 3), the 27.27% 
of the recommendations were based on the high level consistency of results (Class A). 
However, 63.63% of the recommendations were considered Class D/GPP (low level 
evidence related to non-analytic studies, expert opinion, legislation and good practice 
points). [45] 
In the case of AL patients, the literature reports a medley of clinical research related to 
CVC procedures [29], and it is possible to find two departments following the same 
guideline recommendations and reporting different protocols (e.g., mechanical valve 
needleless connectors or split septum connectors, heparin or sodium chloride to CVC 
lock). [31,33] 
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1.3 Central-line associated and related bloodstream infections 
Actually, CLABSI is considered the most costly health-care-associated infection. Annually 
200.000 to 400.000 episodes of CLABSI related to long-term catheters are identified in the 
USA. [29] The NHSN considered CLABSI “as a primary bloodstream infection that 
develops in a patient with a central line in place within 48-hour period before onset of the 
bloodstream infection that is not related to an infection at another site”.[46] 
The CDC has established 5 catheter-associated infection definitions: Localized catheter 
colonization, Exit-site infection, Clinical exit-site infection, Infusate-related bloodstream 
infection, and Catheter-related bloodstream infection (Table I). [31, 40] 
Table I. CDC catheter-associated infection definitions 
Localized catheter colonization Microorganism growth (>15 CFU) from 
catheter tip, subcutaneous segment or 
catheter hub 
Exit-site infection Erythema or induration (≤2 cm) of the 
catheter exit site, in absence of BSI or 
concomitant purulence  
Clinical exit-site infection (tunnel infection) Exit-site infection (≥2cm) of the catheter 
exit site, in absence of concomitant BSI 
Infusate-related bloodstream infection Infusate and blood cultures reportthe same 
microorganism with no other identifiable 
source of infection 
Catheter-related bloodstream infection One positive blood culture obtained for 
peripheral vein and significant catheter 
segment microorganism growth identified 
by DTP, 3:1 ratio, or semiquantitative/ 
quantitative cultures in central-lines (same 
microorganism reported) 
 
CLABSI and CRBSI are usually reported as incidence density (ID) (surveillance studies) 
or as a proportion (pathogen colonization studies). [31] The ID reports the number of 
bloodstream infections per 1000 catheter-days or patient-days, being the catheter-days 
the best choice for analysis. [31]  CLABSI is considered the classic concept in surveillance 
programs, being CRBSI the most used definition, regarding diagnosis and treatment 
purposes. [29] 
Recently, a new MBIm insight was added leading to a hard assessment of management 
CVC procedures, especially in hematology-oncology departments, where the infection due 
to MBIm is common. [19, 47-48] Modified CLABSI definitions related to disruption of 
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mucosal barriers can reduce the number of CLABSI reported. However, CVC 
management could still be the source of CLABSI associated to MBIm. [29] Arne Simon, et 
al., 2016, suggests, in a European systematic review of surveillance of BSI in pediatric 
centers, that pay for performance is an important reason for changing the surveillance 
definitions in U.S.A. [49] 
Zakhourand, et al., 2016, published in Lancet Infectious Diseases a review of the 
Catheter-related infections in patients with hematological malignancies. They present an 
incidence of 14.4 CLABSI rate per 1000 catheter days in AL patients (adjusting CLABSI 
rates to MBIm events, this value decreases to 8.2). [29] These clinical results are based 
on Digiorgio, et al., 2012, clinical research. They developed a modified surveillance 
definition of CLABSI, mCLABSI, considering microbiology disruption of mucosal barriers. 
The study reports 22-bed bone marrow transplant (BMT) and acute leukemia units. 
Considering the new concept, CLABSI rates decrease to 2.0 per 1.000 CVC-days 
regarding 6.0 per 1000 CVC-days in BMT units. This new concept, mCLABSI, is 
associated with an increase of Coagulase-negative staphylococci (CoNS) rates regarding 
enteric pathogens. [50] In 2013, Joshua Lukenbill, et al., suggested in a retrospective 
study of AML and Myelodisplastic syndrome patients undergoing stem cell transplantation,  
a new MCLABSI definition. The study considered OCLABSI as CLABSI original definition 
and it is compared with the new concept. The MCLABSI excludes Viridians group 
Streptococci species in patients with mucositis, Enterococcus, Enterobacteriaceae, or 
Candida species. [35] Finally, study results suggested a lower prevalence of MCLABSI 
than OCLABSI, as previous Digiorgio clinical research. [50] 
1.4 Catheter-related occlusion and thrombosis: Needleless connectors 
and Solution-lock 
Catheter-related occlusion can be observed considering two different sources: 
Nonthrombotic and Trombotic causes. [34] The cloth is considered the most common 
cause of occlusion, however, other causes such catheter pinch-off, precipitation of drugs 
solutions and catheter migration can produce the inability to aspirate blood. [40] Occlusion 
(partial and complete) should be considered when the capacity to blood withdrawal is 
compromised and the ability to flush fluids is lost. The infuse ability is an especial 
condition related to partial occlusion instead of complete occlusion. [34, 40] 
Thrombosis formation can be related to CVC-placements (superior vena cava or upper 
extremity veins) and its characteristics (CVC-lumen). NapalKov, et al., 2013, presented a 
study where CVC-related thrombi formation was observed within 30 days of initial CVC-
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placement in patients with CVC or hemodialysis catheters. [51] Considering the 
thromboses and infection dichotomy, clinical thrombosis manifestations could increase 
CVC-related infection risk. [52] 
The use of thromboembolitic agents by syringe or stopcock method declothing using 
streptokinase, urokinase and alteplase is recommended. [34] 
 Needleless Connectors: Split septum needleless connectors and Mechanical valve 
positive pressure 
Needleless connectors are devices used to create a safety door catheter access. [31] The 
split septum needleless connectors (SSNC) are considered the first generation of these 
devices, followed by the mechanical valve positive pressure (MVC-PP) adaptation. The 
MVC-PP was developed to reduce catheter-related occlusion rates. [26, 34, 53] Both 
devices can be used with sodium chloride or heparin. If flushing-pause and positive-
pressure CVC-lock techniques are not performed, the SSNC can increase the risk of 
occlusion and thrombosis due to tip blood reflux, observed when the syringe or cannula is 
removed. [54-55] The MVC-PP can reduce catheter-related occlusion rates using a 
mechanical valve inside the connector that does not allow the reflux of blood, decreasing 
the probability of small thrombi formation. However, the SSNC reports low infection rates 
than MVC-PP in the literature. [26, 31] 
 Heparin and 0.9% sodium chloride 
The CVC management related to the CVC-lock solution used (heparin or normal saline 
0.9%) still remains controversial and prospective trials are needed. [56] The duration of 
heparin lock, the concentration of heparin solution, heparin induced trombocytopenia or 
coagulophats are limitations for the  use of this solution. [56] However, the fact that 
heparin has a shorter half-life and not a thrombolityc capacity, and that it promotes a 
natural prevention of cloth progression lead to  suggest that heparin is a good solution to 
CVC-lock. [57] 
Theoretical rationale studies support that using heparin to CVC-lock can reduce catheter-
related thrombosis and fibrin deposition (formation film). Bradford, et al., 2016, in their 
systematic review “Heparin versus 0.9% sodium chloride intermittent flushing for the 
prevention of occlusion in long term central venous catheters in infants and children” 
published in “The International Journal of Nursing Studies”, report that most of institutions 
recommend the use of heparin when CVC is not in use. The study reports that clinical 
research is associated with a quality study ranged from low to very low evidence. Indeed, 
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different protocols with several concentrations and frequencies of heparin were related. 
Finally, this study concludes that more well-designed researches are required. [58] 
Alberto Dal Molin, et al., 2015, suggested that normal saline flushing in totally implanted 
venous access devices is not inferior to heparin flushing (with a study power lower than 
56%). In the case of occlusion types, study results revealed a partial occlusion more 
frequent than complete, being only one complete occlusion observed in the saline group. 
The study did not include AL patients and did not consider neutropenia condition. The 
authors present the linical study of Cesaro, et al., 2009, where 203 pediatric patients were 
randomized in a trial that revealed an increased-rate of complications in patients using 
Broviac-Hickman catheters flushing with normal saline solution. [59] 
Healthcare professionals avoid heparin due to the heparin-induced thrombocytopenia [31]; 
however in the particular case of AL patients, thrombocytopenia is considered a frequent 
condition. [40] Abdelkefi, et al. 2007, studied 246 patients with non-tunneled central 
venous catheters comparing the use of continuous infusions of heparin and low-dose 
unfractionated heparin to prevent CRBSI. The study did not reported heparin-induce 
thrombocytopenia and severe bleeding complications between groups (p=1.00). [60] 
Considering Guidelines perspective, the CDC (category II) and EPIC3 (Class D/GPP) 
guidelines do not recommend routinely use of anticoagulants to prevent CRBSI. [31, 45] 
In fact, the use of normal saline to CVC-lock, that are accessed frequently, is considered a 
Class A recommendation by EPIC3 guidelines. However, when the catheter is accessed 
infrequently several doubts still remain, despite that,  low infection rates outcomes reports 
were found. [45]  
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2. Hypothesis Test 
The null hypothesis (H₀) considered: CLABSI assessment of AL patients undergoing 
induction, chemotherapy treatment or aplasia support phases using Hickman catheters is 
not associated [alternative hypothesis (H₁), are associated] to ANC and CVC 
manipulations at the hematology department of the Portuguese Institute of Oncology, 
Porto. 
CVC manipulations and ANC are considered the exposure or event of interest. CLABSI 
and non-CLABSI related with the BCs assessment are considered as the outcome of 
interest. 
2.1 Organigram 
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3. Objectives 
Primary 
CLABSI rates assessment in AL patients using a Hickman catheter 
undergoing chemotherapy treatment, or aplasia support phases 
considering ANC and CVC manipulations; 
Specific  
To evaluate: 
 ANC and CLABSI 
Duration of neutropenia and cumulative prior CLABSI day assessment; 
CLABSI reported considering ANC related; 
Neutropenia Ratio assessment; 
 
 Blood Cultures Collection 
Blood culture assessment related to the episodes, microbiology and infection 
source. 
Transfusion support related to the blood culture collection; 
 
 Catheter-related occlusion 
Catheter-related partial or complete occlusion associated with infection risk;  
Platelet count, Transfusion support and CVC-life associated with catheter-related 
occlusion; 
 
 Mucosal Barrier Microorganism 
Microorganism recovery assessment considering the mucosal barrier injury 
related; 
Mucosal barrier injury microorganism Ratio assessment and CLABSI; 
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4.      Material and Methods 
4.1   Selection and description of participants 
A single-center, retrospective cohort study was performed, including all consecutive AL  
patients using a Hickman CVC for more than 72h, undergoing chemotherapy treatment or 
aplasia support from January 2013 to December 2015, at the Haematology Department of 
the Portuguese Institute of Oncology (Porto). 
Patients older than 18 years old with newly diagnosed or relapsed AL admitted for 
chemotherapy treatment (CT) or aplasia support and with a CVC inserted during the study 
period were included. Patients in supportive care, who had previous hematopoietic stem 
cell transplantation, with clinical septicemia at the moment of the CVC introduction, with 
insertion procedure complications or with acute promyelocytic leukemia diagnosis were 
excluded. 
The number of hematology-oncology patients with long-term catheter inserted since 2013 
to 2015 were 123, being 32 diagnose by acute leukemia (statistics hospital information, 
8th, March 2016). Using the Raosoft® sample size calculator [61] with a 5% margin of 
error, 95% confidence level and 50% response distribution parameters, minimum of 27 
inpatients was recommended in the research. After inclusion and exclusion criteria 
(septicemia n=3, insertion procedure complication n=1), 28 AL patients with a Hickman 
catheter were included. 
4.2  Data collection 
Data concerning each patient’s background was daily collected from the medical records 
since CVC placement day. The daily data assessment ended when the CVC was 
removed from sepsis or in the end of treatment. When the final eligible patient was 
admitted to the study a minimum of one-month follow up was considered. The baseline 
demographic data were collected on the day of CVC placement and the assessment was 
encompassed in every hospital admission. 
4.3  Neutropenia and Central-line infections definitions 
Neutropenia [10] was considered when ANC (Absolute Neutrophil Count) ≤500 cells /µL, 
or when no differential count was available and WBC (White Blood Count) ≤1600 cells/µL 
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was reported (previous statistical correlation analysis). The total of continuous 
neutropenia-days was considered as the duration of neutropenia.  Overall neutropenia-
days related to catheter-days was considered Neutropenia Ratio (NR). Neutropenia days-
prior CLABSI was considered the number of neutropenia-days since the first neutropenia-
day to CLABSI reported. 
 
CLABSI and CRBSI rates were calculated considering BCs yielding an organism (positive 
culture in peripheral vein and at least one CVC-line) per 1000 CVC-days. CLABSI was 
considered in patients with a central line in place within 48-hour period and bloodstream 
infection that is not related to an infection at another site. [10,31] When DTP was reported 
positive, CRBSI was considered. The ratio between the MBIm and the total of 
microorganism recovered was considered MBIm ratio. 
4.4  CVC manipulations and Catheter-related occlusions definitions 
Manipulation was considered in every approach to CVC with at least one open line. One 
manipulation of the CVC was considered every time that the CVC line was opened to 
change the administration sets, collect blood samples or blood cultures (BCs). When 
transfusion support was performed two manipulations were considered. 
The occlusion was considered when the capacity to blood withdrawal was compromised 
and the ability to flush fluids was lost. Partial occlusion (inability to aspirate blood, but 
ability to infuse through the catheter) and complete occlusion (inability to aspirate blood 
and infuse through the catheter) were reported. Catheter-related occlusion was calculated 
considering the occlusion events per 1000 CVC-days. [34] Catheter Lock was considered 
when the solution was injected into the catheter lumen dead space until it was filled to be 
accessed again. [27]  
4.5  Technical department information 
The department consisted of 20 beds distributed among eight double and four single 
rooms, all equipped with positive pressure ventilation and HEPPA filters. AL, non-
Hodgkin/Hodking Lymphoma and Multiple Myeloma patients were admitted in the 
department. The insertion of CVCs was performed by medical staff in an operating room 
[29] located in the department, and daily management of CVCs was performed by nursing 
staff. The ratio nurse/patient ranges between 1:4 and 1:8, being the principal CVC 
maintenance procedures performed in the morning shift when the ratio is higher. During 
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the study period, no other relevant departmental changes were implemented, including 
CVC insertion, CVC management procedures, indication for BCs, and BCs assessment. 
4.6  Blood culture collection and empirical antibiotic use policy 
BCs collected by control indication, the ones non-department collected and hospital 
acquired infections [10, 16] were not included in the study. For every episode with an 
indication for BCs, samples were collected first from a peripheral vein followed by the 
CVC line with no more than five minutes between samples (when samples from CVC lines 
become positive 120 minutes or more before peripheral vein samples, this is known as 
differential time to positivity). [62] BCs collection were performed by one single nurse. BC 
samples were collected with a minimum of 5 ml of blood, when possible, in BACTED 
PLUS Aerobic/F® vials [63] and were analyzed by the microbiology department. In an 
attempt to reduce false positive BC results, due to the positive needleless connector and 
negative hub contamination, needleless connectors were removed before collecting BC 
samples. Large spectrum antibiotherapy was started following the indications of the 2009 
Infectious Diseases Society of America Guidelines for Intravascular Catheter-related 
Infection, that recommend to treat gram-negative bacterial infections in patients 
undergoing neutropenia or septicemia special conditions. [16] 
4.7  Blood Cultures Assessment 
All episodes of positive BCs were analyzed in all hospital admissions, and all negative 
BCs were counted to epidemiological research. The first BCs collection was considered 
as the first episode. If new BCs samples were collected and a second subsequent 
episode was considered and acted upon. In the first 72-hours after the previous episode, 
new first episode was considered when a new microorganism was isolated, when a 
change of the antibiogram, or a change the hub of the colonization in the central line   
occurred. All episodes over 72-hours, to the previous collection, were considered new first 
episode. [64-65] 
The assessment of CRBSI, CLABSI, BSI or colonization was completed by the analysis of 
the microbiological results (Figure I) with a clinical specialist nurse and hematological 
medical specialist evaluation. [2,10,27,31] 
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Figure I. Blood Culture results: BSI, CLABSI and CRBSI assessment  
Peripheral Vein + + + + + - - 
CVC-line 
1.0 mm 
- + -/+ + -/+ + -/+ 
CVC-line 
0.6 mm 
- -/+ + -/+ + -/+ + 
DTP N.A. - - + + N.A N.A 
Microbiological 
Analysis 
BSI CLABSI CLABSI CRBSI CRBSI Colonization Colonization 
 (N.A: not applicable; +:positive; -:negative) 
4.8  Product and practice management 
The management of CVCs followed the CDC (2011) guideline recommendations. 
Hickman catheters (Vygon®) without any antimicrobials were inserted in the subclavian 
vein. All catheters were double lumen (CH/F 7, lumen no. 1=0.6mm, lumen no. 2=1.0mm). 
No antibiotic prophylaxis was performed. Specific technical information about CVC 
management included the use of: chlorhexidine 2% in alcohol 70% solution for needleless 
connector disinfection, split septum needleless connector (Bionecteur, Vygon®), and 
sodium heparin 20 IU/ml (Fibrilin®). Administration sets (not receiving blood, blood 
products or fat emulsions) and needleless connectors were changed in all the blood 
culture collections and no more often than 72-hours to reduce the infection risk associated 
with biofilm formation. [22,64] 
4.9  Data analysis 
Data analysis is conducted using IBM SPSS Statistics for Windows (SPSS Inc., Version 
24.0) licensed by ICBAS-UP (Instituto de Ciências Biomédicas Abel Salazar - 
Universidade do Porto; Master Degree Oncology Program). A continuous variable was 
reported by median and range. Categorical variables were reported as frequency and 
percentages. Any association between two continuous quantitative variables were 
analyzed by Perason´s (r) correlation test. Normality tests (Kolmogorov-Smirnov) reported 
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a sample without normal distribution, considering that, hypothesis tests were analyzed by 
non-parametric test. Differences between categorical measures were performed using 
Mann Whitney U test, and Relative Risk was performed by confidence interval of 95%. A p 
value of ≤ 0.05 was determined to be statistically significant. 
Protection of personal data 
The study was approved by the Ethics Committee (CES IPO: 137/2016) (appendix II) of 
the Portuguese Institute of Oncology (Porto) on 16 June, 2016. All data were treated in 
compliance with the Portuguese Law nº 67/98 of 26 October concerning the protection of 
personal data. 
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5. Results 
In this study 154 hospital admission episodes were analysed (Table II). Twenty eight 
patients diagnosed with AL [AML, n=17(67.7%); ALL, n=11(39.3%), p=0.345] were 
identified, 75% (n= 21) female and 25% (n= 7) male, with a median age of 49 years 
(range, 68 to 23). 
Table II. Baseline Hospital Admissions Characteristics  
Characteristic AML  ALL  p 
Admissions, n(%) 97(62.9) 57(27.1) 0.002 
Age, years, median (range) 49 (68-25) 53(66-23) 0.750 
Gender   Male, n(%) 
               Female, n(%) 
10(6.5) 
87(56.5) 
18(11.7) 
39(25.3) 
0.186 
0.000 
Relapse  Yes 
                No 
18(11.7) 
79(51.3) 
0(0) 
57(37) 
0.000 
0.072 
Admission days(ID), n[median(range)] 1470[12(42-5)] 660[7(38-4)] 0.001 
CVC days, n[median(range)] 1394[12(38-5)] 613[7(35-4)] 0.000 
ANC ≤ 500 cells/µL n[median(range)] 943[15 (38-2)] 269[10(33-1)] 0.002 
Neutropenia Ratio 0.68 0.44  NA 
Number of CVC / patient, median(range) 1(4-1) 1(2-1) 0.200 
CLABSI, n(%) 9(69.2) 4(30.8) 0.852 
CRBSI (% of CLABSI*diagnose) 0(0) 1(25) NA 
AML acute myeloid leukemia ;ALL acute lymphocytic leukemia; NA not applicable 
Considering the distribution of hospital admission by gender associate to age, significant 
lower median age in male group was reported  [male, median 43, range 66 to 23; female, 
median 49, range 68 to 25; p=0.046].  No CLABSI risk was found considering diagnose 
[RR 0.976, 95% CI, 0.887-1.074], relapse [RR 2.267, 95% CI, 0.688-7.472], age [≤50/>50 
years, reference group by sample median age; RR 0.922, CI 95%, 0.325-2.618] and 
gender [RR 2.000, 95% CI, 0.663-6.034]. No CLABSI risk was found considering age, 
diagnosis and gender related (Table III). 
Considering the age [≤50/>50 years] RR ratio reference=1, the relation of CLABSI risk 
related to age was reported (Table IV). No CLABSI was observed in patients younger than 
25 or older than 60 years old. 
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Table III. Age, diagnose and gender CLABSI risk related 
 
 
Age*Diagnose 
AML 
≤50 years(Ref) 
>50 years 
ALL 
≤50 years(Ref) 
>50 years 
Gender*Diagnose 
AML 
Male 
Female 
ALL 
Male 
Female 
Gender*Age 
Male 
≤50 years(Ref) 
>50 years 
Female 
≤50 years(Ref) 
>50 years 
 
CLABSI 
 
 
6(6.2) 
3(3.1) 
 
1(1.8) 
3(5.3) 
 
 
1(1.1) 
8(8.2) 
 
3(5.3) 
1(1.8) 
 
 
2(7.1) 
2(7.1) 
 
5(4) 
4(3.2) 
 
Non-CLABSI 
 
 
55(56.7) 
33(34) 
 
24(42.1) 
29(50.9) 
 
 
9(9.3) 
79(81.4) 
 
15(26.3) 
38(66.7) 
 
 
14(50) 
10(35.7) 
 
65(51.5) 
52(41.3) 
 
RR CI 95% 
 
 
1.180 (0.314-4.433) 
  
 
0.427 (0.047-3.858) 
 
 
 
1.088 (0.151-7.823) 
 
 
  6.500 (0.725-58.674) 
 
 
 
0.750 (0.123-4.589) 
 
 
1.000 (0.282-3.550) 
 
Table IV.CLABSI risk age related 
 
Age 
 
≤25 
>25 years 
 
≤30 
>30 years 
 
≤35 
>35 years 
 
≤40  
>40 years 
 
≤45  
>45 years 
 
≤50 years 
>50 years 
 
 
CLABSI 
 
0(0) 
13(8.4) 
 
1(0.6) 
12(7.8) 
 
2(1.3) 
11(7.1) 
 
2(1.3) 
11(7.1) 
 
3(1.9) 
10(6.5) 
 
7(4.5) 
6(3.9) 
 
 
Non-CLABSI 
 
19(12.3) 
122(91.6) 
 
26(16.9) 
115(74.7) 
 
48(31.2) 
93(60.4) 
 
53(34.4) 
88(57.1) 
 
57(37) 
84(54.5) 
 
79(51.3) 
62(40.3) 
 
 
RR CI 95% 
 
- 
 
 
0.392(0.053-2.888) 
 
 
0.378 (0.087-1.642) 
 
 
0.327 (0.075-1.424) 
 
 
0.470 (0.135-1.639) 
 
 
0.922 (0.325-2.618) 
 
 
 
RR ratio 
 
- 
 
 
0.43 
 
 
0.41 
 
 
0.35 
 
 
0.51 
 
 
1 
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≤55 years 
>55 years 
 
10(6.5) 
3(1.9) 
92(59.7) 
49(31.8) 
1.699 (0.489- 5.909) 1.84 
≤60 years 
>60 years 
 
13(8.4) 
0(0) 
112(73.4) 
28(18.2) 
- - 
≤65 years 
>65 years 
13(8.4) 
0(0) 
125(81.2) 
16(10.4) 
- - 
 
Reasons for hospital admission were induction treatment [32 (20.8%)], aplasia support [48 
(31.2%)], CT [70 (45.4%)], and CT + aplasia [4 (2.6%)].  Induction and CT hospital 
admissions were summarized by AML and ALL CT protocols [7+3, 66 (42.9%); SWOG, 22 
(14.3%); Consolidations, 7 (4.5%); BF12, 1 (0.6%); VC, 1 (0.6%)] and [hyper CVAD A1, 31 
(20.1%); hyper CVAD B2, 17 (11%); All Rez BFM90, 3 (1.9%) and BFM90, 6 (3.9%)]. 
Considering CT protocols related to CLABSI, differences by AL groups were reported, 
AML [6 (46.2%) 7+3, 3 (23.1%) SWOG and ALL [(3 (23.1%) hyper CVAD A, 1 (7.7%) 
hyper CVAD B] [p=0.005]. However, no superior CLABSI risk between protocols was 
found:  SWOG vs 7+3 [RR 1.500,95% IC, 0.307 to 6.197], SWOG vs hyper CVAD´s [RR 
1.636, 95% IC, 0.301 to 8] and 7+3 vs hyper CVAD´s [RR 3.273, 95% IC, 0.886 to 12]. 
5.1 Hematological recovery and CLABSI risk 
An overall of 1393 blood samples were analyzed. A hemoglobin median ≤9 g/dl in all 
admissions was identified [median 8.17, range 15.7 to 4.4]. Considering hemoglobin at the 
first admission day, significant differences were found between induction (median 8.45, 
range 13.8 to 7.3), aplasia support (median 7.75, range 9.1 to 5.3) and CT (median 9.55, 
range 12.6 to 7.2), p=0.000. The study reported 0.25 thrombocytopenia ratio 
(thrombocytopenia days related to overall hospital admission days) considering 
thrombocytopenia (≤20.000 cells/µL) among 541 days. AML patients (median 6, range 33 
to 0) revealed superior cumulative thrombocytopenia days (≤20.000 cells/µL) than ALL 
patients (median 3, range 18 to 0) (p=0.008). Considering CLABSI and non-CLABSI 
identified, no significant differences between the thrombocytopenia distribution were 
identified (p=0.736). Considering the number of platelets count ≤20.000 cells/µL at CVC 
insertion day related to CLABSI, CLABSI risk was not found [RR 2.500, CI 95%, 0.261 to 
23.937]. 
                                                          
1
 Induction CT 
2
 Consodlidation CT 
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Reporting ANC days (Table V) by hospital admissions phases, no significant CLABSI risk 
association between induction versus aplasia support was found (RR 0.736, 95% CI, 
0.311-1.745). No CLABSI was reported during the CT phase (Figure II). 
Table V. ANC and Hospital Admissions related to CLABSI 
ANC by days 
(median,range) 
Induction Aplasia 
Support 
CT p 
≤ 500 cells/µL 19(38-1) 12(23-3) NA 0.000 
> 500 cells/µL 6(28-1) NA 6(13-4) 0.323 
≤ 500 cells/µL prior CLABSI  
≤ 500 cells/µL CLABSI*  
≤ 500 cells/µL non-CLABSI*  
> 500 cells/µL non-CLABSI * 
6.5(13-2) 
14.5(30-9) 
16(26-2) 
6(28-1) 
4(9-1) 
12(20-8) 
13(15-7) 
NA 
NA 
NA 
NA 
6(13-4) 
0.285 
0.067 
0.000 
0.545 
* Hospital Admissions with CLABSI or non-CLABSI reported 
Figure II. CLABSI and ANC related by Hospital Admission  
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5.2 Catheter baseline characteristics and infection risk 
In total, 42 Hickman catheters (median 1; range 4 to 1 by patient) were inserted, 
concerning 2130 hospital admission days (ID) including 2007 catheter days. On 
admission, the CVC was placed in ≤7 days in 90.5% events (median 1, range 17 to 1). No 
CLABSI was observed in CVC placed after >7 days of admission. CVC was placed in right 
Subclavian vein in 36 (85.7%) events. No statistical significances were found regarding 
CVC laterality and CLABSI (p=0.463). Considering ANC at the moment of CVC insertion, 
CLABSI risk was not found between neutropenia and non-neutropenia patients [RR 1.091, 
CI 95%, 0.989 to 1.204]. The CVC was removed in bacteriemia cases.  (n=5;11.9%), 
insertion site infection (n= 4;9.5%) and after patient death (n=1; 2.4%); the remaining 32 
CVC were removed at the end of treatment (76.2% cases). Twelve CVCs had more than 
100 days-life (median 67, range 188 to 8). No admission in the intensive care unit related 
to CLABSI was reported during the study period. 
Local infection signs in the CVC exit - site were reported at least in one day in 26 (46.9%) 
cases [induction 15 (53.6%), aplasia support 7 (25%), CT 4 (14.3%) and CT + aplasia 
support 2 (7.1%)]. Considering admissions related to neutropenia, the risk of exit-site 
infection were higher in induction and aplasia support [RR 3.392, CI 95%, 1.407 to 9.040] 
than in CT. When CLABSI was considered, local infection signs were reported in 2 
(22.2%) cases without microorganism recovered after microbiology local scrub analyses. 
Considering total parenteral nutrition (TPN) and CLABSI reports, in 7 (4.5%) hospital 
admissions TPN was reported. In CLABSI cases identified, no TPN was administrated in 
the least 72 hours previous to the event. In hospital admissions related to BCs episode, 
TPN was used in 6 (85.71%) cases. 
5.3 Transfusion support and CLABSI 
An overall of 595 transfusions were reported (Table VI). A median of 2 transfusions (range 
30 to 0) was performed by admission episode. Superior number of transfusion support 
was identified when CLABSI was reported at hospital admission (p=0.011). When CLABSI 
was reported, only 1 (7.7%) BCs was performed at transfusion support time. In 9 (69.3%) 
cases, transfusion support was reported between 24/72-hour period prior CLABSI. Other 
3 (29%) cases were observed ≥72-hours after transfusion support. A median of 3 
admission days prior to first transfusion support (range 27 to 1) were identified. 
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Table VI. Transfusion support related by diagnosis 
 AML ALL p 
Overall 
n[median(range)]* 
438[4(30-0)] 157[1(22-0)] 0.011 
Induction* 
Aplasia Support* 
CT* 
CT+ Aplasia Support* 
230[8(30-0)] 
170[5(11-0)] 
18[0(3-0)] 
20[6(11-3)] 
73[5(22-1)] 
65[4(8-1)] 
16[0(5-0)] 
3[3(3-3)] 
0.356 
0.274 
0.397 
0.500 
5.4 Catheter-related occlusions 
A total number of 16 occlusion days (median 1, range 5 to 1) among 10 occlusion events 
were observed (Table VII). Partial occlusion was identified 8 (80%) times (median 1, 
range 2 to 1), being complete occlusion reported 2 (20%) times (median 3.5, range 5 to 
2). Considering platelet count at the occlusion day, no significant differences were found 
between partial (median 26.5, range 306 to 7) and complete (median 155.5, range 168 to 
143) occlusions (p=0.400). Whereas placement CVC day, a median of 67.5 (range 172 to 
17) days to the occlusion was reported. Considering the hospital admission days related 
occlusion, earlier occlusion events (≤72-hour) after first admission day was observed 
more frequently than late occlusion events (>72h-hour; median 3, range 27 to 0) 
[p=0.010]. When occlusion events were identified in induction, its occurred in hospital 
admission superior to 15 days [RR 3.000, CI 95%, 0.914 to 3.000]. No occlusion after 
transfusion support or 72-hour after/before CLABSI were observed. Complete occlusions 
were always identified in non-thrombocitopenic patients, being partial occlusion reported 
in 2 (25%) cases undergoing thrombocytopenia. No catheter-related thromboses were 
reported. Overall 4.98 catheter-related occlusion rates per 1000 catheter-days, including 
partial 3.98 and complete 0.99, were reported. 
Table VII. Catheter-related occlusions development 
Oclussion 
type 
Oclussion 
days (OD) 
1.0 cvc 
line OD 
0.6 cvc 
line OD 
Admission 
day 
Platelets 
Count* 
CVC life-
days 
Complete 2 - 2 16 168 92 
Complete 5 5 - 0꙳ 143 43 
Partial 1 1 1 27 306 27 
Partial 1 1 1 1 247 95 
Partial 1 1 1 2 23 92 
Partial 1 1 1 3 7 172 
Partial 2 2 - 17 21 17 
Partial 1 - 1 3 20 100 
Partial 1 1 1 5 30 18 
Partial 1 1 1 1 123 41 
*First occlusion day; Oclussion reported at the moment of the admission꙳ 
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5.5 Neutropenia, CVC Manipulations and CLABSI risk 
An overall of 1393 blood samples, 595 transfusions, 145 BCs, and 304 CVC-line isolated 
substitutions were observed. Overall 1212 neutropenia-days were reported. Considering 
the duration of neutropenia, induction reported superior median of neutropenia-days 
(median 19, range 38 to 1) than aplasia support (median 12, range 23 to 3) [p=0.000]. 
When neutropenia-days prior CLABSI was considered, no statistical significance were 
found between induction (median 6.5, range 13 to 2) and aplasia support (median 4, 
range 9 to 1), [p=0.285]. 
A total number of 3032 CVC manipulations by catheter were reported (median 15, range 
95 to 3) considering a median of 1 CVC manipulations by day (range, 5 to 0) (Table VIII). 
CVC-lines were used with perfusion iv (at least one day) in 142 hospital admissions, being 
only used for blood samples and transfusion support in 12 aplasia support admissions 
without CLABSI reported.  
CLABSI was always reported in neutropenia admissions within cases presenting a median 
number of CVC manipulations superior to 15. The number of CVC manipulations 
increases concerning cumulative neutropenia days [r=0.752, p=0.000 with a R2 = 0.605]; 
non-neutropenia days [r=0.051, p=0.564 with a R2 = 0.004]. (Figure III) 
Figure III: CVC manipulations correlated to neutropenia days 
 
Taking neutropenia condition into account, CLABSI risk is increased considering CVC 
manipulations [CLABSI group, mean ±SD, 27.89±3.199; non-CLABSI group, mean±SD, 
20.82±1.189; p=0.046] (Figure IV). 
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Figure IV : Overall CVC manipulations related to CLABSI in neutropenia 
  
 
 
Table VIII. CVC manipulations ANC related by admission 
 Induction Aplasia Support CT p 
ANC ≤ 500 cells(median,range)* 33.5(77-1) 18(38-4) NA 0.000 
ANC > 500 cells* 5(23-1) NA 5(19-3) 0.095 
ANC ≤ 500 cells/µL,prior CLABSI* 10(12-2) 7(15-2) NA 0.546 
ANC ≤ 500 cells/µL,CLABSI*¥ 37.5(51-21) 20(38-14) NA 0.067 
ANC ≤ 500 cells/µL,non-CLABSI*¥ 33.5(77-1) 13(24-4) NA 0.000 
ANC > 500 cells/µL,non-CLABSI*¥ 5(23-1) NA 5(19-3) 0.147 
NA not applicable; ¥ Hospital Admissions with CLABSI or non-CLABSI reported 
Considering the induction phase as reference, manipulation ratio (median of 
manipulations by admission; induction=1, aplasia support=0.45, CT=0.12) was reported. 
No statistical significances were found between the number of CVC manipulations in 
neutropenic days prior CLABSI in both induction (median 10, range 12 to 2) and aplasia 
p=0.046 
49 
 
support (median 7, range 15 to 2), p=0.762. Also no significant CLABSI risk association 
between induction and aplasia support was found (RR 0.736, 95% CI, 0.311–1.745). 
5.6 Blood Cultures and Microbiological Recovery 
BCs were collected at 48.7% (median 0, range 6 to 0) of all hospital admissions, being 
positive in 21 (10.4%) reports. No CLABSI was identified after first positivity result; after 
first negative result, 2 (9.5%) positive BCs were reported. No positive BCs were reported 
after three negative results. Considering the cumulative days prior BCs assoictaed with 
ANC by hospital admissions and BCs related by ANC (Table IX), no positive BCs were 
reported by ANC>500 cells/µL in AML patients, and only 1 (4.7%) positive BC was 
reported by ANC>500 cells/µL in ALL patients. 
Table IX. Cumulative days prior Blood Cultures related to ANC by hospital 
admissions. 
Days Induction Aplasia Support CT p 
ANC ≤ 500 cells/µL 
(median,range)* 
5(19-1) 4(9-1) NA 0.356 
ANC > 500 cells/µL * 4(6-3) NA 2(8-1) 0.254 
BCs were summarized by hospital admission phases: induction [median 2, range 6 to 0], 
aplasia support [median 1, range 3 to 0] and CT [median 0, range 1 to 0]. Considering the 
number of BCs related to CLABSI by hospital admission phases, BCs have been always 
negative in non-neutropenia induction phases when at least one BCs episode was 
reported. None CLABSI was observed over three BCs collection in all hospital 
admissions. (Table X)  Fifty-five (%) CT admissions did not report BCs episode. BCs 
collection risk was superior in induction phase than in  aplasia support [RR 1.624, CI 95%, 
1.095 to 1.362].  Comparing aplasia and CT, superior risk of BCs collection was reported 
in aplasia support [RR 4.952, CI 95%, 2.849 to 9.103]. Superior BCs collection risk was 
observed when neutropenia was reported [RR 5.688, CI 95%, 3.419 to 10.245]. 
Considering BCs results related to ANC at the moment of the sample, no superior risk to 
positive reports were found among neutropenia and non-neutropenia population [RR 
4.375, CI 95%, 0.715 to 82.238]. 
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Table X.  Blood Cultures results related to episodes and ANC 
 AML ALL p 
Blood Cultures, n[median(range)] 105[1(6-0)] 40[0(6-0)] 0.066 
 
Positive 
Negative 
 
14[0(2-0)] 
91[1(5-0)] 
 
7[0(3-0)] 
33[1(6-0)] 
 
0.623 
0.451 
 
Positive ANC ≤ 500 cells/µL  
Positive ANC >500 cells/µL 
Negative ANC ≤500 cells/µL 
Negative ANC >500 cells/µL 
 
14[0(2-0)] 
0 
76[1(5-0)] 
14[0(3-0)] 
 
6[0(3-0)] 
1[0(1-0)] 
23[1(6-0)] 
10[0(1-0)] 
 
0.805 
0.121 
0.054 
0.181 
 
First episode 
Positive 
Negative 
Second episode 
Positive 
Negative 
Third episode 
Positive 
Negative 
 
92[2(3-1)] 
14[0(1-0)] 
78[1(3-0)] 
11[0(2-0)] 
0 
11[1(2-1)] 
2[0(1-0)] 
0 
1(1-1) 
 
39[1(6-1)] 
7[0(1-0)] 
32[1(6-0)] 
1[0(1-0)] 
0 
1[1(1-1)] 
0 
0 
0 
 
0.815 
0.421 
0.723 
0.112 
NA 
0.909 
NA 
NA 
NA 
 
Febrile resolution (≤72-hours) was observed in 119 (82.1%) first BCs episode, been 
reported in 12 (92.3%) cases when CLABSI identified. No positive BCs were identified in 
second and third episode and no fourth BC episode was observed. There were 8 cases 
(10.7%) when there was a previous antibiotherapy administration before the first BC 
sample; in these cases  no CLABSI was reported. Considering the number of BCs with 
febrile resolution (≤72- hours) undergoing neutropenia, no significant differences were 
found between AML [n (71), median 1, range 2 to 0]  and ALL [n (27), median 1, range 3 
to 0) (p=0.449) patients. In the particular case of a number of BCs with febrile resolution 
(>72-hours) undergoing neutropenia, statistical significance was observed between 
patients diagnosed with AML [n (20), median 0, range 1 to 0] and ALL [n (3), median 0, 
range 2 to 0) (p=0.015). Considering the number of BCs with febrile resolution (>72- 
hours) undergoing non-neutropenia, in all cases [3 (2.1%)], rate of ANC decline was 
reported. 
Considering CVC-lines microorganism recovery, 1.0 mm CVC-line was positive in 12 
(92.3%) cases when CLABSI reported. When colonization is reported,0.6 mm CVC-line 
was always positive 5 (100%). At least one CVC line (1.0 mm or 0.6 mm) was negative in 
5 (31.25%) cases when CLABSI was reported. 
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BCs results were summarized by CLABSI, microorganism recovered, and 
symptomatology prior BCs (Table XI).  
Table XI. Microbiological Blood Cultures results and Symptomatology related 
Source Gram - Gram + Symptomatology ≤72h prior BCs* 
CLABSIα - S.Aureus  
S.Mitis 
Hypotension and Respiratory Distress 
CLABSI - S.Mitis - 
CLABSI K.Pneumoniae - - 
CLABSI Serratia 
Marcescens 
S.Epidermidis - 
CLABSI E.Coli  Chills 
CLABSI - S.Aureus - 
CLABSI E.Coli - Constipation 
CLABSI E.Coli - Constipation 
CLABSI P.Aeruginosa - Chills 
CLABSI E.Coli - Hypotension Headaches, Nausea and 
Vomiting 
CLABSI P.Aeruginosa - Chills 
CLABSI K.Pneumoniae - Chills 
CLABSI K.Pneumoniae - Chills 
Colonization P. Aeruginosa - Abdominal Pain and Headaches 
Colonization K.Pneumoniae - Chills 
Colonization K.Pneumoniae - - 
Colonization - S. Salivarius - 
Colonization K.Pneumoniae - - 
Secondary 
BSI 
E. Coli - Mucositis and Diarrhea 
Secondary 
BSI 
E. Coli - Abdominal Pain, Mucositis and 
Diarrhea 
Secondary 
BSI 
P. Aeruginosa - Chills 
*Fever associated; non-MBIm (S);
 α 
CRBSI 
The only gram-negative bacteria reported by ALL patients were Klebsiella Pneumoniae, 
being the remaininggram-negative bacteria associated with AML patients. E.coli (n=4; 
30.7%) was the most representative microorganism identified in CLABSI events, being the 
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Klebsiella Pneumoniae (n=3;60%) the most representative microorganism linked to CVC 
colonization events. No previous colonization reports to CLABSI were observed. 
The study suggested an overall 0.80 MBIm ratio associated with colonization events.  No 
fungus species was identified. (Table XII) Overall, CRBSI and CLABSI rates per 1000 
catheter-days were reported as 0.49 [AML 0 and ALL 1.63) and 6.47 [AML 6.45 and ALL 
6.52], considering overall 0.63 MBIm ratio associated [AML 0.62 and ALL 0.69]. 
Table XII. Microorganism recovery: CLABSI, Colonization and MBIm related  
Microorganism Recovered, n(%) AL (overall) AML ALL 
Gram + 
CLABSI 
MBI 
Streptococcus Mitis 
Streptococcus Salivarius 
Others 
Staphylococcus Aureus 
Staphylococcus Epidermidis 
Colonization 
MBI 
Streptococcus Mitis 
Streptococcus Salivarius 
Others 
Staphylococcus Aureus 
Staphylococcus Epidermidis 
 
6 
2(40) 
2(100) 
- 
3(60) 
2(66.7) 
1(33.3) 
2 
2(100) 
1(50) 
1(50) 
- 
- 
- 
 
4(66.7) 
1(33.3) 
1(100) 
- 
2(33.3) 
1(50) 
1(50) 
1(50) 
1(100) 
- 
1(100) 
- 
- 
- 
 
2(33.3) 
1(50) 
1(100) 
- 
1(50) 
1(100) 
- 
1(50) 
1(100) 
1(100) 
- 
- 
- 
- 
Gram – 
CLABSI 
MBI 
Escherichia Coli 
Klebsiella Pneumoniae 
Serratia Marcescens 
Others 
Pseudomonas Aeruginosa 
Colonization 
MBI 
Escherichia Coli 
Klebsiella Pneumoniae 
Serratia Marcescens 
Others 
Pseudomonas Aeruginosa 
 
10 
8(80) 
4(50) 
3(37.5) 
1(12.5) 
2(20) 
2(100) 
4 
3(75) 
- 
3(100) 
- 
1(25) 
1(100) 
 
7(70) 
5(71.44) 
4(80) 
- 
1(20) 
2(28.6) 
2(100) 
1(25) 
- 
- 
- 
- 
1(100) 
1(100) 
 
3(30) 
3(100) 
- 
3(100) 
- 
- 
- 
3(75) 
3(100) 
- 
3(100) 
- 
- 
- 
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6. Discussion 
AL patients are considered a special population due to the higher number of hospital 
admissions and the difficulty to access catheter-related complications across time. Clinical 
research, CVC-related, in AL patients undergoing high dose CT is infrequent, probably 
due to the low incidence of the disease and to the difficulty to find an appropriate 
population sample [7, 29]. Studies regarding AL that are only based on the number of 
patients could and should be considered a bias due to the fact that multiple hospital 
admissions of these patients that  lead to a different statistical distribution. Indeed, this 
study revealed no statistical differences between AL diagnoses associated with the 
number of patients, and the diagnose distribution was superior in AML patients related to 
hospital admissions phases (induction, aplasia support and CT).  
CLABSI could be considered a rare event in non-neutropenic patients; in consequence AL 
patients seem to be an optimal CLABSI research population considering neutropenia 
ratios reports and CVC use. Taking this into account, aplasia support should be included 
in clinical studies, being mostly focused on induction reports. [28] 
Infection risk and CLABSI in AL patient 
Considering the CLABSI definition and the fever as non-specific sign of infection, when a 
BC collection is negative the infection source is considered unknown. AL patients reported 
BCs collection in induction, aplasia support and CTs phases, being BCs risk superior in 
hospital admissions related to neutropenia. The duration of neutropenia could improve a 
superior number of CLABSI events in induction, reporting superior duration of neutropenia 
that aplasia support. Even considering a superior duration of neutropenia associated with 
induction, no significant statistical differences was found between the CLABSI risk and 
cumulative neutropenia-days previous to CLABSI among induction and aplasia support 
phases. Being neutropenia ratio and negative ANC ≤500 cells/µL BCs results tendency 
superiors in AML patients, a higher infection risk could be considered in this group. 
However, AML and ALL patients did not report significant statistical CLABSI risk 
differences, in consequence, induction and aplasia support (concerning  AML and ALL 
patients) could be considered similar hospital admissions CLABSI associated with 
neutropenia .  
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HAST, CLABSI rates and CVC management 
Studies indicate that the CVC is an indispensable tool in these patients. [26] Blood 
samples, transfusion support and BCs collection could be considered the most 
representative causes of CVC manipulations, mostly in induction and aplasia support. In  
patients undergoing CT consolidation fewer CVC manipulations were observed.   
Several organizations used CLABSI surveillance programs to assess infections 
associated with CVC insertion and maintenance procedures. Surveillance data can 
provide information needed to improve patient outcomes and the quality of patient care. 
CLABSI rate reports are based in diferent departments data (ICU, hematology-oncology, 
blood marrow transplant, acute leukemia units…) in both  adult and pediatric populations. 
[27] In the particular case of hematology-oncology departments, a low number  of hospital 
admissions can be associated with the multidisciplinarity of these units that include also 
patients with solid tumors [67], influencing infection rates. Even considering CLABSI 
assessment related by pathology, in several cases CLABSI rates could not be associated 
with a specific central-line device, being CVC management details not reported in mostly 
cases [29, 30]. These findings can be the basis of a high frequency of low level CVC 
guideline recommendations. Being HAST framework based on patient, practice and 
product variables this could be considered a good tool associated with effectiveness of 
clinical research (Figure V). 
Figure V. Patient, Product and Practice related to Acute Leukemia Patients
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This study indicated neutropenia as the most important variable related to adult AL 
patient. Biofilm formation [21,22] could be associated with patient, product and practice 
variables and it is considered a modifiable risk factor concerning CRBSI rates. [13] 
CVC management procedures as blood samples drawn at the moment of CVC-line 
change, CVC-line maintenance every 72-hours (changing needleless connectors and 
administration sets), administration sets removed in BCs episodes, optimal choice of 
needleless connectors used (positive pressure mechanical valves are associated to high 
infection rates) [13,19-20], turbulent flush and positive-pressure locking techniques, could 
reduce unnecessary CVC manipulations and influence CLABSI and CRBSI reports. [11] 
Besides that, some CVC procedures (changing needleless connectors and administration 
sets in all BCs episodes) are used in the attempt to improve product colonization risk 
reduction and could be on the basis of high frequency of febrile episode resolution in 72-
hour period reported. For example, if a needleless connector was colonized, changing this 
product as previously referred could remove the possible infection source.  Besides, some 
of these practices could influence the low number of second BC episodes and CRBSI 
rates reported. 
Neutropenia and CVC manipulations related to CLABSI risk 
Neutropenia is considered a major CLABSI risk factor [12]. This study suggested that 
aplasia (neutropenia, anemia, and thrombocytopenia) increases the number of CVC 
manipulations (Figure VI), mostly due to several blood samples, transfusion support and 
BCs collection. [9-19]. This study reported a manipulation ratio higher in induction than in 
aplasia support and CT. However, similar CLABSI rates were reported between induction 
and aplasia, being a CLABSI considered a rare event in CT. This could be explained 
considering that cumulative neutropenia days increases the number of CVC 
manipulations. This fact associated to neutropenia increases CLABSI risk. In 
consequence, this study suggests that neutropenia and CVC manipulations association 
are major CLABSI risk factors. Therefore, when appropriated CVC management, isolated 
or cumulative CVC manipulations in non-neutropenia could be considered minor CLABSI 
risk factors.  
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Figure VI. Aplasia, CVC manipulations and CLABSI 
 
Considering neutropenia-days prior to CLABSI and biofilm formation risk period (48/72-
hour period) [15], risk phase is higher between days 9 to 15 in induction and days 1 to 7  
in aplasia support. (Figure VII) 
Figure VII. CLABSI risk period related to neutropenia hospital admissions
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CVC management and occlusions among hospital admissions 
This study reported an higher number of transfusion support and blood samples in 
induction, CT, and higher frequency in aplasia support admissions. When nurse-to-patient 
ratio is poor [29], the transfusion support procedure management could be affected due to 
the elapsed time between transfusion support ending and infusion resume or transfusion 
withdrawal. If nurse-to-patient ratio is modified, quality of CVC-care considering catheter-
related occlusions and CLABSI/CRBSI rates should be considered. This study did not 
report catheter-related occlusions associated with transfusion support and it could be 
considered a good quality CVC-management indicator.  
Catheter-related occlusion and infection should not be dissociated. [7, 34, 52] An 
adequate clean sweep of the catheter-lumen using sodium chloride 0.9% through push-
pause technique seems to be essential to secure CVC pattency and reduce biofilm 
formation risk. [31, 45, 54-56] This study reports the use of heparin to CVC-lock after 
catheter-lumen clean sweep. Considering heparin short-life, low heparin concentration 
(20-30 UI) and non-bleeding reports, the use of heparin to CVC-lock could be considered 
of dismal risk. In this study we indicate that heparin could reduce cumulative fibrin 
deposition (possible biofilm and thrombi formation source) [21, 22, 40, 60] in the first 
hours after CVC manipulation based on the CRBSI and catheter-related occlusion rates 
reported. Considering that, the relationship between heparin and catheter-related 
infections should be studied. [31,45,59] 
In the last decade the MVC-PP replaced SSNC to reduce the use of heparin and catheter-
related occlusions. [67] The design of an MVC-PP versus SSNC showed an important 
structural difference between them: the MVC-PP allows the fluids to enter and return 
inside the connector through the internal valve; on the other side the SSNC allows the 
fluids to enter and return inside the connector without resistance. Flushing CVC above 0.1 
ml is enough to create positive pressure in MVC-PP and if just a little more product is 
infused it is expelled. Even using heparin CVC-locks, biofilm formation risk related to 
cumulative fibrin deposition through the internal valve seems to be on the basis of 
superior infection rates associated with MVC-PP. [26] Using SSNC, CVC-line clamp 
before connector syringe withdrawal could be considered a positive-pressure technique. 
(Figure VIII) 
When the syringe is removed, empty space generated inside the connector is created. It 
does not allow the blood reflux into the catheter tip, and consequently the probability of 
occlusion by small thrombi formation is reduced. In the particular case of partial 
occlusions reported, the study reported the resolution of all events in less of 48-hours. In 
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consequence, this study suggested that the use of heparin to CVC-lock could help to 
reduce and resolve partial occlusions. 
Figure VIII. CVC-line clamp positive-pressure technique 
 
 
Catheter-related occlusions were usually reported in the literature in second and third 
week after CVC-placement. [51] This study reported only two partial occlusions 
considering ≤30 days CVC-placement. Besides, this study suggested that catheter-related 
occlusion risk was not associated with platelet count; so CVC-management could be 
considered a major catheter-related occlusion risk factor versus CVC-placement time and 
platelet count at the occlusion-day. 
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Blood Cultures Collection protocols, sets and CLABSI 
Concerning biofilm formation risk, BCs should be collected every 72-hour period until 
symptomatic recovery. However, considering our BCs episode results and if not clinically 
indicated, BCs should be only obtained until second episodes; and when positive BCs are 
identified; the new BCs collection should be weightened. 
Taking BCs episode risk, undergoing hospital admissions and neutropenia into account, 
BCs should be always obtained in patients undergoing neutropenia (induction and aplasia 
support). However, considering the positive BCs results tendency (it is not ANC related 
and CLABSI is always reported undergoing neutropenia) and the maximum of one BCs 
episode related to CT phases, the first BCs collection undergoing non-neutropenia 
(induction and CT) should be weightened.  
Considering BCs obtained undergoing non-neutropenia and febrile resolution trending, the 
need of BCs collection in the first febrile episode should be equated after exclusion of non 
septic febrile causes (as drugs and transfusion related side effects)  leaving the sample 
collection for a second event. Considering negativity trending after second negative 
results, the only new BCs episode should be considered clinically indicated. Several 
doubts concerning the number of culture specimens set when obtaining BCs were 
considered. The NCCN recommends obtaining one peripheral venipunctures and one 
catheter culture for distinguishing between CRBSI and BSI. [10] Considering this 
recommendation, a false CLABSI negative could be identified in one third of CLABSI 
reported in this study, if BCs had been collected from one of CVC-lines and it was 
negative reported and positive peripheral vein, BSI had been reported in place of CLABSI 
in these cases. (Figure IX)  
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Figure IX. Blood Cultures Protocol in AL patients ANC related
 
 
CLABSI rates to zero [9] and MBIm. Is it possible in AL patients naturally link this to 
neutropenia? 
Colonization through mucosal disruption and epithelial loss could be on the basis of 
CLABSI. [12-15] This study reported a high rate of MBIm (Viridians group, Streptococci 
and Enterobacteriaceae). When examining MBIm with CLABSI rates assessment by 
HAST insight [7], the impact of CVC management procedures remains unknown. [10] The 
study suggested a similar MBIm ratio among AL patients considering the same practice 
and device used. MBIm recovery seems to be related to neutropenia when CLABSI 
reported, especially with the cumulative neutropenia-days, being not associated with the 
duration of neutropenia itself. However, the CVC manipulations could be on the basis of 
the MBIm related to CLABSI, too[10]. Considering that, several difficulties to understand 
the colonization source, patient or healthcare professional, are revealed. 
The relationship between MBIm and neutropenia could be an appropriate insight to 
assess the balance between patient and practice related to CLABSI. In fact, CLABSI rates 
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associated with high MBIm ratios undergoing neutropenia could be considered a good 
infection control indicator related to CVC management. Considering the dichotomy 
associated with the possible infection source, MBIm assessment should not be 
dissociated from CLABSI, being zero CLABSI rates a difficult aim to achieve in infection 
control programs, in these patients. 
6.1     Scope and limitations 
The clinical research related to neutropenia and CVC management in AL patients is 
scarce. The most important advantage of our study is that it was performed in a specific 
immunocompromised population with an accurate department infection control description 
and in a homogeneous sample. This is a retrospective study and a lack of documentation 
could be possible. However, our electronic medical record reports a systematic 
description of CVC procedures by nurse team. Multicenter studies are needed to increase 
the population study, however, due to a medley of clinical research in hematology-
oncology patients related to CVC management procedures, is possible to find two 
departments following the same guideline recommendations without reports of different 
CVC procedures (e.g., mechanical valve needleless connectors or split septum 
connectors, heparin or sodium chloride to CVC lock). Besides, it could be considered an 
infection control assessment bias. Considering AL and CLABSI rare events, single-center 
prospective cohort studies should not be performed due to high risk of department 
changes across the years (bias). Prospective studies with a multicenter larger size and 
several homogenic management CVC procedure descriptions should be performed to 
increase the sample and assess these findings. 
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7. Conclusion 
The study concludes that: 
 In neutropenic patients, undergoing induction therapy or in aplasia support, 
CLABSI risk increases along with cumulative neutropenia days prior CLABSI and 
CVC manipulations. 
 MBIm ratio should be included to CLABSI rates assessment.  
 Patient, product and practice should be considered to effectiveness of CVC clinical 
research. 
The study suggests that: 
 Different protocols concerning BCs collection related to ANC should be 
considered.  
 BCs should be obtained in a peripheral vein and both CVC-lines to prevent false 
negative results. 
 The relationship between heparin and catheter-related infections should be 
studied. 
 Catheter-related occlusion risk is not related to platelet count, being the CVC-
management considered a major catheter-related occlusion risk factor. 
 
Future Perspectives 
The successful reduction of CVC complications is related to the quality of its care. The 
CVC is a sterilized product, being infected by the patient, professional or environment. 
Future high-quality CVC management descriptions considering patient, product and 
practice, could help to increase the infection control knowledge. Taking infection risk class 
and manipulation ratio prevision into account, an appropriate central line device 
associated with the patient could be considered (midline, PICC, Hickman…). In fact, new 
tools could be assessed to reduce CVC manipulations. However, several departments 
around the world reports limited-resources, being the CVC procedure descriptions (ex. 
positive pressure techniques) a wonderful help to reduce infection rates in these cases. In 
the particular case of departments with nurse-poor-ratio reduced and related to CLABSI 
risk increased, nurse staff reinforcement should quickly be considered.            
The development of CVC manipulation protocols could help to reduce the infection risk 
associated. It is not only important in patients with high manipulation ratio related, in fact, 
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is possible to find institutions where the CVC is not manipulated in isolated admissions to 
reduce the infection risk, being blood samples collected in a peripheral vein. If the patient 
has a CVC line, blood samples should not be collected from a peripheral vein to reduce 
the number of CVC manipulations. Protocols of CVC manipulations concerning 
performance and cumulative number should be implemented. 
BCs protocol development could help to reduce unnecessary BCs collection and improve 
quality of life to these patients. 
Considering the MBIm, microbiological studies should be developed to find the source of 
the colonization (appendix III). If the patient is considered the source, intervention 
programs considering mouthwashes and special nutrition should be implemented. If the 
professional is considered the source, education program (considering theoretical and 
practical insight) seems to be the best option.  
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 Needleless connector devices: Acute Leukemia inpatients, CLABSI and Mucosal 
Barrier Injury Microorganisms insight 
1. Introduction 
The purpose of this study is to understand the mucosal barrier injury 
microorganisms(MBIm) related to Central-line associated bloodstream infections through 
the assessment of acute leukemia patients using Hickman® Catheter, considering 
microbiological recovery of needleless connector devices, Blood cultures, and Local CVC 
insertion site. 
Infectious diseases are important causes of morbidity and mortality in hematology 
oncology patients. Patients with AL, have an higher risk of neutropenia due to high-dose 
chemotherapy treatments and to malignancy itself.1-2-3 Multiple chemotherapy cycles, 
antibiotic resistant bacteria, high transfusion rates are known predisposing factors that 
increase  incidence and prevalence of bloodstream infections (BSI).4-5-6 
Healthcare and Technology Synergy (HAST) framework considered patient, product and 
practice as the central elements related by effectiveness of clinical research associated to 
central venous catheters.7Insertion CVC procedure was largely studied and compared 
with the management CVC procedure. The real value of CVC management still remain 
unclear due to the low description and few management details reports.8 
Regarding BSI in patients with central-line devices, CLABSIis considered the classic 
definition in  surveillance programs,being CRBSI (Catheter-related bloodstream infection) 
the most used definition regarding diagnosis and treatment purposes.9 Zakhour and 
colleagues published in  Lancet Infection Diseases (2016) a review of the Catheter-related 
infections in patients with haematological malignances suggesting an incidence of 14.4 
CLABSI rate per 1000 catheter days.9Recently the new conceptof MBIm  was added 
leading to a harder assessment of the management CVC procedures, especially in 
hematology-oncology departments, where the infection due to MBIm is 
common.10Adjusting CLABSI rates to MBIm events, this value decreases to 8.2 in acute 
leukemia patients.9 
The colonization of the intraluminal route from the catheter tubing connection, catheter 
hub or IV fluids, are considered the most important infection threats.11 Several studies 
have identified the biofilm formation by individual multi-resistant pathogens as a principal 
source of infection.12-13 The methillin-resistant S.aureus, vancomycin-resistant 
Enterococcus, C.difficile, extended-spectrum β-lactamase-producing gram-negative bacilli 
and Candida  are considered the most important microorganisms that cause nosocomial 
 infection.14-15 If colonization progresses and clinical infection occurs, cultures should be 
obtained and empiric antibiotics started at the time of presentation.15-16 The management 
of blood cultures collection in neutropenic patients with fever is not consensual in the 
literature concerning the number of sets obtained through the catheter and peripheral 
vein.However,there is no doubt about the importance of collecting microbiological blood 
from central catheter lines and peripheral vein to determine the source of bloodstream 
infection based on the differential time to positivity(when samples are collected from CVC 
lines and become positive 120 minutes or more before samples from peripheral vein, it is 
known as differential time to positivity).18.16-17-18 
Several doubts still remain concerning the real influence of management CVC procedures 
in the incidence of CLABSIS associated to MBIm.10 Maria Guembe and colleagues 
published in Journal of Clinical and Microbiology(2015) an original research relating the 
importance of needleless connector’s microbiology assessment to suggest the source of 
CVC colonization and infection, especially in higher  infection risk populations as acute 
leukemia patients.19 
2. Objectives 
a) Identified MBIm in CVC devices associated to CVC management or Patient 
source; 
b) Report a colonization map of the NCs in every internment; 
c) Understand the relationship between NC and hub colonization; 
d) Improve a new microbiological assessment based on NC cultures; 
 
3. Hypothesis Test 
The null hypothesis is considered: 
H₀: MBIm recovered in Blood Cultures collection are not associated to CVC management 
procedures related to CLABSI. 
The alternative hypothesis is considered: 
H₁: MBIm recovered in Blood Cultures collection are associated to CVC management 
procedures related to CLABSI. 
NCs, BCs, Swipe CVC insertion site microorganism recovered are considered the 
exposure or event of interest. CLABSI related to management CVC procedures or MBIms 
are considered the outcomes of interest.  
 4. Material and Methods 
Selection and Description of Participants 
A single-center prospective cohort study is performed, including all consecutive AL in 
patients using a Central Venous Catheter for more than 72h, undergoing chemotherapy 
treatment (CT)or in aplasia support, since September 2017 to February 2018.  
Patients older than 18 years old, with newly diagnosed or relapsed AL, admitted in CT or 
aplasia support, with CVCs introduced in the study period are included.  
Data Collection 
Data concerning patient’s background is prospective collected. The daily data assessment 
ends when the CVC is removed by sepsis or end of use. When last patient is eligible to 
the study a minimum of one month follow up is considered. The baseline demographic 
data is collected in the placement day of CVC and assessment is encompassed in every 
hospital admission. 
Technical Department Information 
Twenty bed units distributed along eight double rooms and four single rooms equipped 
with positive pressure ventilation and HEPPA filters. Acute Leukemia, non-Hodgkin, 
Hodgkin Lymphoma and Multiple Myeloma patients are admitted in the department. The 
insertion of CVCs is performed by medical staff in a proper room, specially equipped for 
the procedure and only used with this intent9,located at department and daily 
management of CVCs is performed by trained nurse staff.  
Blood Cultures Collection and Empirical antibiotic use policy 
BCs are collected by control indication16 and non-department and hospital acquired 
infections are not included in the study. For every episode with indication for BCs, 
samples are collected first from peripheral vein followed by CVC lines with no more than 
five minutes between them The BC collection is performed by one nurse. BCs samples 
are collected (with a minimum of 5ml of blood, when possible) in to BACTED PLUS 
Aerobic/F® vials17 and analyzed by the microbiological department. Needleless 
connector’s (NC) devices are removed before BCs collection. When BCs are collected, an 
insertion site swipe is performed. When negative bloodstream is reported and positive 
NCs devices are reported, colonization is considered  
Large spectrum antibiotherapy is started as the Guidelines for Intravascular Catheter-
related Infection of Infectious Diseases Society of America (IDSA, 2009) recommend to 
 gram-negative bacteria infections in patiens undergoing neutropenia or septicemia special 
conditions.20 
Blood Cultures Assessment 
All episodes of positive blood cultures are analyzed in all the admissions, and all negative 
blood cultures are counted to epidemiological research. NC are analyzed and removed 
every 72h or in every BC episodes. When microbiology results are positive in NC and 
negative in BC collection (hub and bloodstream), management CVC is considered the 
source of NC colonization. If NC and BC are positive with the same microorganisms, 
colonies count between hub and NC determine the source of infection. However if NC and 
BC collection reports different microorganisms, the patient is considered as infection 
source.  If the insertion site swipe and NC reports positivity with the same microorganism, 
and BC are negative, management of CVC is considered as colonization CVC source. If 
BCs are positive with the same microorganism reported in NC and site swipe, CVC 
management is considered as infection source21 (Fig 1).  
 
NCs Flowchart (Fig 1) 
 
 The assessment of CRBSI or CLABSI is complete by the analysis of the microbiological 
results by clinical specialist nurse and hematologymedical specialist evaluation. Blood 
cultures collected by control indication and non-department and hospital acquired 
infections are not included in the study. 
 
Product and practice management 
The management of CVCs followed the CDC (2011) guidelines recommendations.22 
Hickman® catheters (Vygon®), are inserted, without any antimicrobials, in the subclavian 
vein with double Lumen (CH/F 7, No.1=0.6 and No.2=1.0). No antibiotic prophylaxis is 
performed. Specific technical information of CVC management includes the use of: 
chlorhexidine 2% in alcohol 70% solution to needleless connector disinfection [split 
septum needleless connector (Bionecteur®) (Fig 2) and Octopus®(Fig 3 ). Sodium 
heparin 20UI/ml (Fibrilin®) is used to CVC lock.  
 
 
Bionectecur® (Fig 2)          Octopus® (Fig 3)                                                                                              
Protection of personal data 
These study is attached to the “Central-line associated bloodstream infection rates and 
blood cultures collection assessment in Acute Leukemia inpatients: retrospective cohort 
study” thesis approved by the Ethics Committee (CES IPO: 137/2016) of the Portuguese 
Institute of Oncology (Porto) in 16-June-2016. All data are treated in compliance with the 
Portuguese Law nº 67/98 of 26 October concerning the protection of personal data. 
5. Human Resources 
 
The human resources involve Nurse, Medical and Technics staff of the Oncology-
hematology and Microbiology department.  
 
  
6. Study Budget 
 
Laboratory : 
 Microbiological cultures of all specimens collected 
Management of NCs for microbiological cultures   
2500€ 
Consumables (material and laboratory resources) 
Estimative of 100 NC devices/month 
4000€ 
Publications Fees 
e.g. Journal of Hematology-Oncology 
 
2000€ 
Total 8500€ 
 
 
7. Chronogram 
 
Month Project Ethics 
Data 
Collection 
Data 
Analysis  
Publication 
May      
June      
July      
August      
September      
October      
November      
December      
January 
2018 
     
February      
March      
April      
May      
June 
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